A Prospective, Open-label, Multicenter Study With Blinded Over-reading Characterizing the Efficacy and Safety of 99mTc-EC-DG in the Evaluation of Coronary Artery Disease (CAD)
Latest Information Update: 05 Jan 2023
Price :
$35 *
At a glance
- Drugs Tc 99m ethylenedicysteine deoxyglucose (Primary) ; Tc 99m sestamibi
- Indications Coronary artery disease
- Focus Diagnostic use
- Sponsors CellPoint
- 28 Jan 2021 Planned End Date changed from 1 Mar 2020 to 1 Jan 2023.
- 28 Jan 2021 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2022.
- 28 Jan 2021 Status changed from recruiting to active, no longer recruiting.